Chemoprevention of Human Colorectal Tumors

$0P50FY2002CANIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications & trials

Paper 39700179 Paper 39514554 Paper 39470352 Paper 39455893 Paper 39433569 Paper 39403935 Paper 39390609 Paper 39371158 Paper 39298276 Paper 39279378 Paper 39261223 Paper 39142659 Paper 39116880 Paper 39113096 Paper 39107309 Paper 38959011 Paper 38915758 Paper 38869494 Paper 38829053 Paper 38781545 Paper 38717519 Paper 38662083 Paper 38609521 Paper 38478628 Paper 38457748 Paper 38381705 Paper 38352476 Paper 38352348 Paper 38320723 Paper 38319515 Paper 38280960 Paper 38266106 Paper 38234851 Paper 38161092 Paper 38086385 Paper 38063199 Paper 37948357 Paper 37939140 Paper 37776855 Paper 37745323 Paper 37723590 Paper 37645761 Paper 37598013 Paper 37595586 Paper 37591207 Paper 37566230 Paper 37565753 Paper 37535375 Paper 37501622 Paper 37500728 Paper 37484200 Paper 37406887 Paper 37402062 Paper 37351909 Paper 37345735 Paper 37342060 Paper 37339979 Paper 37230894 Paper 37212770 Paper 37212422 Paper 37199193 Paper 37165219 Paper 37131822 Paper 37116182 Paper 37080163 Paper 37067199 Paper 37066222 Paper 37014860 Paper 37001882 Paper 36967355 Paper 36947820 Paper 36940317 Paper 36868526 Paper 36801389 Paper 36788099 Paper 36773599 Paper 36747709 Paper 36712023 Paper 36652559 Paper 36399356 Paper 36371607 Paper 36315911 Paper 36214223 Paper 36209796 Paper 36154788 Paper 36109689 Paper 36029239 Paper 35997715 Paper 35995657 Paper 35963368 Paper 35959988 Paper 35952628 Paper 35941803 Paper 35937503 Paper 35909243 Paper 35861852 Paper 35833954 Paper 35750529 Paper 35737913 Paper 35718227

Abstract

Revised Abstract: The tremendous advances made in understanding the molecular details of cancer have so far failed to result in corresponding reductions in the mortality rates of the most common epithelial cancers. The goal of this project is to discover and apply emerging molecular genetic insights from colorectal cancer to rationally devise new strategies for blocking tumorigenesis. In work previously supported by the GI SPORE, a novel combinatorial chemopreventive strategy was developed using a combination of a potent irreversible inhibitor of epidermal growth factor receptor kinase and a low dose of the NSAID, sulindac. This combination proved to be particularly effective against intestinal tumors and was not associated with adverse side effects. The current proposal builds on this paradigm by proposing: 1) characterization of compounds and targets in mouse models, 2) mechanistic evaluation of molecular pathways, and 3) clinical evaluation of the most promising strategies.

View original record on NIH RePORTER →